您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Myelin Oligodendrocyte Glycoprotein Peptide(35-55),mouse,rat TFA
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Myelin Oligodendrocyte Glycoprotein Peptide(35-55),mouse,rat TFA
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议
100mg电议

产品名称
MOG (35-55) (TFA)
产品介绍
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) TFA 是中枢神经鞘的一个次要成分。Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA 有致脑炎活性,诱导 T 细胞增殖。Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA 诱导 Th1 细胞因子反应以及相对高水平的 IgG 抗体产生。Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA 引发复发缓解性神经系统疾病,伴有广泛的斑块样脱髓鞘。
生物活性

Myelin OligodendrocyteGlycoproteinPeptide (35-55), mouse, rat (MOG (35-55)) TFA is a minor component of CNS myelin. Myelin OligodendrocyteGlycoproteinPeptide (35-55), mouse, rat TFA has encephalitogenic activity and induces T cell proliferative. Myelin OligodendrocyteGlycoproteinPeptide (35-55), mouse, rat TFA induces Th1 cytokine response as well as relatively high levels ofIgGantibodies. Myelin OligodendrocyteGlycoproteinPeptide (35-55), mouse, rat TFA produces a relapsing-remittingneurological diseasewith extensive plaque-like demyelination[1][2][3].

体外研究
(In Vitro)

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55); 0-50 μg/mL; 72 h; lymph nodes cells) TFA induces T cell proliferative and secretes Th1 cytokines including IFN-γ, TNF-α, IL-10, IL-4 and IL-5. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA increases the level of IgG[1].

体内研究
(In Vivo)

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55); 200 μg (0.2 mL); i.p.; once, for 38 d) TFA has encephalitogenic activity in HLA-DR2 (DRB1*1501) mice[1].

Animal Model:HLA-DR2 (DRB1*1501) mice[1]
Dosage:200 μg (0.2 mL)
Administration:Intraperitoneal injection; once, for 38 days
Result:Resulted in paralysis of both hind and forelimbs.
分子量

2695.97

性状

Solid

Formula

C120H178F3N35O31S

Sequence

Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys

Sequence Shortening

MEVGWYRSPFSRVVHLYRNGK

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Protect from light, stored under nitrogen

Powder-80°C2 years
-20°C1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

溶解性数据
In Vitro: 

H2O : ≥ 50 mg/mL(18.55 mM)

*"≥" means soluble, but saturation unknown.

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM0.3709 mL1.8546 mL3.7092 mL
5 mM0.0742 mL0.3709 mL0.7418 mL
10 mM0.0371 mL0.1855 mL0.3709 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (protect from light, stored under nitrogen)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: PBS

    Solubility: 100 mg/mL (37.09 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在本网站选购。